COMPARISON
Liraglutide vs Lixisenatide
6 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Liraglutide is authorised or registered in 10 and Lixisenatide in 8 of the 10 registers read. Liraglutide: highest phase Phase 4 (after approval). Lixisenatide: No trial states a phase. 15 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Liraglutide | Lixisenatide | |
|---|---|---|
| Registered trials differs | 518 clinicaltrials.gov · 2026-10-03 | 75 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Liraglutide openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Soliqua 100/33 openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2009-06-30 ema · 2026-10-03 | 2017-01-11 ema · 2026-10-03 |
| EU withdrawn on differs | Not checked no record of "withdrawnOn" for liraglutide | 2024-08-27 ema · 2026-10-03 |
| ATC code differs | A10BJ02 ema · 2026-10-03 | A10AE54 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Liraglutide | placebo | Lixisenatide | placebo |
|---|---|---|---|---|
| Nausea | 26.4% | 7.4% | 24.8% | 6.5% |
| Diarrhoea | 13.1% | 6.1% | 10.1% | 8.1% |
| Nasopharyngitis | 12.4% | 9.3% | 9.1% | 9.0% |
| Vomiting | 9.0% | 2.1% | 10.3% | 2.6% |
| Hypoglycaemia | 8.7% | 3.3% | 18.4% | 16.4% |
| Headache | 8.3% | 5.9% | 9.6% | 6.8% |
| Constipation | 8.8% | 3.1% | - | - |
| Decreased appetite | 6.6% | 1.2% | - | - |
| Upper respiratory tract infection | 6.0% | 4.7% | - | - |
| Dyspepsia | 5.3% | 1.3% | - | - |
| Dizziness | - | - | 8.3% | 6.3% |
| Hypertension | - | - | 4.6% | 4.9% |
| Influenza | - | - | 4.4% | 2.4% |
| Angina pectoris | - | - | 4.3% | 5.5% |
Trial register Liraglutide: 42 placebo-controlled trials; Lixisenatide: 11. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Liraglutide side effects · Lixisenatide side effects
LEGAL STATUS
Approval in each country read
| Country | Liraglutide | Lixisenatide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Not on the register | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
15 registered trials include both
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study ACTIVE_NOT_RECRUITING · updated 2026-08-13 |
|---|---|
| NCT07188545 | Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Rea ACTIVE_NOT_RECRUITING · updated 2025-09-23 |
| NCT03492580 | A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants COMPLETED · updated 2025-06-25 |
| NCT06449235 | Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh UNKNOWN · updated 2024-07-16 |
| NCT05136287 | SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULT COMPLETED · updated 2024-02-28 |
| NCT02244164 | Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. TERMINATED · updated 2023-02-16 |
| NCT02787551 | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FR COMPLETED · updated 2022-03-25 |
| NCT04196231 | Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) COMPLETED · updated 2020-10-22 |
| NCT04184947 | Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists COMPLETED · updated 2020-03-11 |
| NCT03959865 | GLP-1 REceptor Agonists and Real World EvIdeNce UNKNOWN · updated 2019-05-22 |
| NCT02231658 | Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion TERMINATED · updated 2018-10-17 |
| NCT01973231 | Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes COMPLETED · updated 2017-02-09 |
| NCT01175473 | Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes COMPLETED · updated 2016-11-28 |
| NCT01596504 | Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without COMPLETED · updated 2016-10-14 |
| NCT02501850 | The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) UNKNOWN · updated 2015-07-21 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.